Chilton Capital Management’s Benitec Biopharma BNTC Stock Holding History

Chilton Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	269
2021 Q4	$0	Buy	+4	New	+$223	﹤0.01%	648

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chilton Capital Management's BNTC Position: Q1 2022 in Review

Chilton Capital Management sold out of Benitec Biopharma (BNTC) in Q1 2022, closing a stake of 4 shares.

Chilton Capital Management first reported a position in BNTC in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 21 funds tracked by Wall St. Rank hold BNTC as of Q1 2022.

Chilton Capital Management reported no remaining Benitec Biopharma position as of Q1 2022 after selling out during the quarter.
Chilton Capital Management sold 4 Benitec Biopharma shares in Q1 2022.
Chilton Capital Management first reported a position in Benitec Biopharma in Q4 2021 and held it in 1 quarter.
Chilton Capital Management's Benitec Biopharma position peaked at $0 in Q4 2021.
21 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2022.

Based on Chilton Capital Management's 13F filing for Q1 2022, filed 16 May 2022.